GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Sloan Ratio %

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Sloan Ratio % : -19.80% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

SciClone Pharmaceuticals (Holdings)'s Sloan Ratio for the quarter that ended in Dec. 2023 was -19.80%.

As of Dec. 2023, SciClone Pharmaceuticals (Holdings) has a Sloan Ratio of -19.80%, indicating there is a warning stage of accrual build up.


SciClone Pharmaceuticals (Holdings) Sloan Ratio % Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Sloan Ratio % Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial -14.33 15.38 0.50 16.14 -19.80

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.36 16.54 17.45 -15.69 -19.80

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals (Holdings)'s Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Sloan Ratio % falls into.



SciClone Pharmaceuticals (Holdings) Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

SciClone Pharmaceuticals (Holdings)'s Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(1227.113-1535.971
-557.265)/4375.389
=-19.80%

SciClone Pharmaceuticals (Holdings)'s Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(1227.114-1535.972
-557.266)/4375.389
=-19.80%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. SciClone Pharmaceuticals (Holdings)'s Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 689.282 (Jun. 2023 ) + 537.832 (Dec. 2023 ) = HK$1,227 Mil.
SciClone Pharmaceuticals (Holdings)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 634.046 (Jun. 2023 ) + 901.926 (Dec. 2023 ) = HK$1,536 Mil.
SciClone Pharmaceuticals (Holdings)'s Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 278.165 (Jun. 2023 ) + 279.101 (Dec. 2023 ) = HK$557 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, SciClone Pharmaceuticals (Holdings) has a Sloan Ratio of -19.80%, indicating there is a warning stage of accrual build up.


SciClone Pharmaceuticals (Holdings) Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines